Stay updated with breaking news from Oncoextra Test. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) has been given a consensus rating of “Moderate Buy” by the fourteen analysts that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average twelve-month price objective among […]
Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) General Counsel James Herriott sold 415 shares of the company’s stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $61.50, for a total transaction of $25,522.50. Following the completion of the sale, the general counsel now directly owns 6,943 […]
Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) Director D Scott Coward sold 706 shares of the stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $61.50, for a total transaction of $43,419.00. Following the completion of the transaction, the director now directly owns 43,122 shares in […]
Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) Director D Scott Coward sold 706 shares of the stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $61.50, for a total transaction of $43,419.00. Following the sale, the director now owns 43,122 shares in the company, […]
Exact Sciences (NASDAQ:EXAS – Get Free Report) had its price objective decreased by analysts at Canaccord Genuity Group from $100.00 to $90.00 in a report released on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the medical research company’s stock. Canaccord Genuity Group’s price target would suggest a potential upside of 50.18% […]